IO Biotech

IOBT

Market cap $137M

Overview Fund Activity

2.08 USD

+0.17

8.9%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

2.07

-0.01

0.48%

1 day

8.9%

5 days

4.52%

1 month

58.78%

3 months

38.67%

6 months

128.57%

Year to date

124.67%

1 year

170.87%

5 years

-86.71%

10 years

-86.71%

About: IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Employees: 78

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

24% more funds holding

Funds holding: 21 [Q1] → 26 (+5) [Q2]

22% more capital invested

Capital invested by funds: $20.8M [Q1] → $25.3M (+$4.49M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

1.34% less ownership

Funds ownership: 28.94% [Q1] → 27.6% (-1.34%) [Q2]

38% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 8

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$4

92% upside

Avg. target

$4

92% upside

High target

$4

92% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Morgan Stanley

Matthew Harrison

$4

Overweight

Maintained

12 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about IOBT published over the past 30 days

IO Biotech, Inc. (IOBT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

IO Biotech, Inc. (NASDAQ:IOBT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Mai-Britt Zocca - Founder, President, CEO, Principal Financial Officer & Director Qasim Ahmad - Chief Medical Officer Amy Sullivan - Chief Financial Officer Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.

IO Biotech, Inc. (IOBT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that members of its senior management team will provide a corporate update and participate in one-on-one meetings at the following upcoming investor conferences: Event: Morgan Stanley 23rd Annual Global Healthcare ConferenceLocation: New York, New YorkFireside Chat Date & Time: Tuesday, September 9, 2025 at 7:45 am ETPresenters: Mai-Britt Zocca, PhD, President and CEO, Amy Sullivan, CFO, and Qasim Ahmad, MD, CMOWebcast Link: Here Event: H.C.

IO Biotech Announces Participation in Upcoming Investor Conferences

Zacks Investment Research

IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's What You Should Know

IO Biotech, Inc. (IOBT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's What You Should Know

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Announced clinical improvement in progression free survival observed in pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (pembrolizumab) for the treatment of first-line advanced melanoma, but statistical significance narrowly missed; company plans to meet with FDA this fall to discuss data and next steps for a potential regulatory submission Ended second quarter with approximately $28.1 million in cash and cash equivalents; the company expects that our cash position, together with €12.5 million in proceeds from the second tranche of the European Investment Bank (EIB) loan facility received on July 4, 2025, will be sufficient to continue funding our operations into the first quarter of 2026 Corporate presentations are planned for the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025 NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today reported financial results and business highlights for the second quarter of 2025.

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma

IO Biotech's phase 3 melanoma trial showed a strong PFS benefit, especially in true 1st-line and PD1-negative patients, despite narrowly missing statistical significance. I believe the FDA should accept a submission based on these compelling, double-blind, randomized trial results, which show consistent benefits across subgroups. Key risks include potential FDA rejection, a dilutive cash raise, and limited US patient enrollment, but upcoming catalysts could strengthen IOBT's position.

IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma

IO Biotech's cancer vaccine shows improvement in late-stage study goal

IO Biotech said on Monday its experimental cancer vaccine, in combination with Merck's Keytruda, showed improvement in a late-stage study goal, but was not statistically significant.

IO Biotech's cancer vaccine shows improvement in late-stage study goal

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-1.00), (p=0.056), with median PFS (mPFS) of 19.4 months vs. 11.0 months, respectively; the results on the primary endpoint narrowly missed the study's statistical significance threshold of p≤0.045 In patients enrolled in this study without prior neo-adjuvant/adjuvant anti-PD-1 treatment (n=371), patients treated with Cylembio plus pembrolizumab achieved improvement in PFS, HR: 0.74 (CI 0.56-0.98) (nominal p=0.037), with mPFS of 24.8 months vs.

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET to disclose the topline results of the pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvant) in combination with pembrolizumab vs. pembrolizumab alone as a first-line treatment for unresectable or metastatic (advanced) melanoma.

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

Zacks Investment Research

IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy?

After reaching an important support level, IO Biotech, Inc. (IOBT) could be a good stock pick from a technical perspective. IOBT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy?

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that Mai-Britt Zocca, PhD, the company's President and CEO, along with Amy Sullivan, the company's CFO, and Qasim Ahmad, MD, the company's CMO, will be participating in a fireside chat at the TD Cowen 6th Annual Oncology Summit: Insights for ASCO & EHA being held virtually May 27-28, 2025. Additionally, Dr. Zocca will be presenting and Dr. Zocca, Amy Sullivan, and Dr. Ahmad will be participating in one-on-one investor meetings at the Jefferies Global Healthcare Conference to be held June 3-5, 2025 in New York, NY.

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

See News Rankings

Charts implemented using Lightweight Charts™